A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Linifanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 13 Jul 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.